Assenagon Asset Management S.A. Sells 84,256 Shares of McKesson Corporation $MCK

Assenagon Asset Management S.A. lowered its position in shares of McKesson Corporation (NYSE:MCK) by 44.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 107,438 shares of the company’s stock after selling 84,256 shares during the quarter. Assenagon Asset Management S.A.’s holdings in McKesson were worth $92,973,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Meiji Yasuda Asset Management Co Ltd. increased its stake in McKesson by 0.5% in the 4th quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,262 shares of the company’s stock valued at $1,855,000 after buying an additional 11 shares during the last quarter. Investment Research Partners LLC boosted its stake in shares of McKesson by 0.7% during the 4th quarter. Investment Research Partners LLC now owns 1,624 shares of the company’s stock worth $1,332,000 after buying an additional 11 shares during the last quarter. IHT Wealth Management LLC boosted its stake in shares of McKesson by 0.9% during the 4th quarter. IHT Wealth Management LLC now owns 1,196 shares of the company’s stock worth $981,000 after buying an additional 11 shares during the last quarter. Obsidian Personal Planning Solutions LLC grew its holdings in shares of McKesson by 2.9% in the 3rd quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock valued at $346,000 after acquiring an additional 12 shares in the last quarter. Finally, LRI Investments LLC increased its position in shares of McKesson by 12.1% in the fourth quarter. LRI Investments LLC now owns 111 shares of the company’s stock valued at $91,000 after acquiring an additional 12 shares during the last quarter. 85.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Brian S. Tyler sold 8,463 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $775.13, for a total value of $6,559,925.19. Following the sale, the chief executive officer owned 14,382 shares in the company, valued at approximately $11,147,919.66. This represents a 37.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 699 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $735.27, for a total value of $513,953.73. Following the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,667,592.36. This represents a 23.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 20,285 shares of company stock worth $15,546,137 in the last quarter. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on MCK shares. Wells Fargo & Company dropped their target price on McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. William Blair assumed coverage on McKesson in a research note on Tuesday, April 28th. They issued an “outperform” rating for the company. Barclays lowered their price target on McKesson from $1,050.00 to $925.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 10th. Raymond James Financial set a $970.00 price objective on McKesson in a report on Thursday, March 5th. Finally, Evercore reissued an “outperform” rating on shares of McKesson in a research note on Thursday, March 5th. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, McKesson presently has a consensus rating of “Moderate Buy” and an average price target of $960.53.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson announced a $179 million, state-of-the-art pharmaceutical distribution center in Moore, Oklahoma, a sign of continued investment in its healthcare logistics network and capacity expansion. McKesson Selects Moore, Oklahoma for $179 Million State-of-the-Art Pharmaceutical Distribution Center
• Positive Sentiment: Related reports say the new Moore facility will be a 330,000-square-foot distribution hub and could create 200+ jobs, reinforcing McKesson’s role as a key healthcare supply-chain operator. McKesson picks Moore for 330,000-square-foot distribution hub, 200+ jobs expected
• Positive Sentiment: McKesson also announced its first-quarter fiscal 2027 earnings release date for August 5, which gives investors a clear near-term catalyst to watch. McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
• Positive Sentiment: The company’s annual ideaShare 2026 event highlighted momentum with independent pharmacies, which may support customer relationships and future distribution demand. McKesson ideaShare 2026 Fuels Momentum for Independent Pharmacies
• Neutral Sentiment: Zacks noted that MCK is a trending stock among users, reflecting elevated investor interest rather than a fundamental change in outlook. McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: A separate portfolio update from TCW mentioned McKesson, but it does not appear to be a company-specific catalyst. TCW Concentrated Large Cap Growth Fund Q1 2026 Portfolio Activity

McKesson Stock Performance

Shares of NYSE:MCK opened at $768.14 on Thursday. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00. The company has a market capitalization of $89.93 billion, a P/E ratio of 19.97, a price-to-earnings-growth ratio of 1.26 and a beta of 0.31. The company has a 50-day simple moving average of $781.47 and a 200 day simple moving average of $841.13.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. The firm had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The business’s revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $10.12 earnings per share. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. As a group, equities analysts forecast that McKesson Corporation will post 44.28 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s payout ratio is presently 8.53%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.